LEXINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a company developing innovative diagnostic products to improve patient health, today announced the T2Candida® Panel will be the focus of a company symposium, one slide session and three poster presentations during ASM Microbe 2016, integrating the American Society of Microbiology’s two premier events, the General Meeting and the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The annual meeting will take place June 16-20 in Boston.
The schedule for presentations by T2 Biosystems and its collaborators is as follows:
COMPANY SYMPOSIUM: “Sepsis Diagnosis: It’s Time for a New Gold Standard”
Date/Time: Friday, June 17 from 7 – 9 p.m.
Location: Westin, Grand Ballroom B
Overview: A discussion among leading experts who will share real clinical experiences with the T2Candida Panel to improve patient outcomes and cost management, as well as examine other diagnostic tests in development.
SLIDE SESSION: “Early Experience with T2Candida and Antifungal Utilization at a Large Community Health System”
Sponsored By: Lee Memorial Health System
Time: Sunday, June 19 from 3:30 - 3:45 p.m.
Location: Renaissance, Pacific Grand Ballroom F
POSTER PRESENTATION: “Performance Evaluation of the T2Candida Panel in the ICU Setting - Data from an Ongoing Study”
Sponsored By: Statens Serum Institut
Time: Monday, June 20 from 12:30 – 2:30 p.m.
Location: BCEC, Exhibit and Poster Hall, Halls A and B
POSTER PRESENTATION: “Verification of T2Candida Panel for the Identification of Candida Species in EDTA-preserved Whole Blood”
Sponsored By: Geisinger Health System
Time: Monday, June 20 from 12:30 – 2:30 p.m.
Location: BCEC, Exhibit and Poster Hall, Halls A and B
POSTER PRESENTATION: “Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals”
Sponsored By: University of Houston: College of Pharmacy
Time: Monday, June 20 from 12:30 - 2:30 p.m.
Location: BCEC, Exhibit and Poster Hall, Halls A and B
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. For more information on risk factors for T2 Biosystems, Inc.’s business, please refer to the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 9, 2016, under the heading “Risk Factors,” and other filings the Company makes with the Securities and Exchange Commission from time to time. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.